What is Zymeworks's ZW171 — R&D?

Zymeworks (ZYME) reported ZW171 — R&D of $1.15M in Q1 2026.

What does ZW171 — R&D mean?

This metric represents the total investment and resource allocation dedicated to the research and development activities for the specific therapeutic candidate or platform identified as ZW171. It captures the strategic commitment to advancing this asset through the clinical pipeline, reflecting the company's focus on innovation and product development. Investors use this to gauge the intensity of development efforts and the prioritization of this specific asset within the broader R&D portfolio.

Zymeworks ZYME ZW171 — R&D

Other product segments

Expense for other preclinical and research programs

$6.37M+226%

Zanidatamab

$4.62M-58.7%

ZW191

$2.85M-2.7%

ZW220

$2.14M+439%

ZW251

$2.03M+1,085%

Similar metrics at other companies

NRIXNX-1607 — R&D

$1.19M-39.4%

AXSMAZD7325 — Research And Development Expense

$2.3M—

SRRKRD Expense Srk181 — Research And Development Expense

$36K-96.8%

NRIXZelebrudomide (NX-2127) — R&D

$1.91M+72.3%

INSMINS1148 — R&D

$10M—

ARQTOther program costs — R&D

$95K-92.0%

Other financials

Income statement

See full

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

See full

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

See full

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

See full

Market cap$1.79B+125%

Profitability

See full

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

See full

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's zw171 — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zymeworks's ZW171 — R&D?: Zymeworks (ZYME) reported ZW171 — R&D of $1.15M in Q1 2026.
What does ZW171 — R&D mean?: This metric represents the total investment and resource allocation dedicated to the research and development activities for the specific therapeutic candidate or platform identified as ZW171. It captures the strategic commitment to advancing this asset through the clinical pipeline, reflecting the company's focus on innovation and product development. Investors use this to gauge the intensity of development efforts and the prioritization of this specific asset within the broader R&D portfolio.